| Primary |
| Breast Cancer |
22.4% |
| Prostate Cancer |
16.5% |
| Premedication |
12.2% |
| Non-small Cell Lung Cancer |
7.5% |
| Drug Use For Unknown Indication |
6.7% |
| Hypertension |
4.4% |
| Prophylaxis |
4.3% |
| Pain |
4.2% |
| Breast Cancer Metastatic |
2.5% |
| Nausea |
2.5% |
| Gastric Cancer |
2.4% |
| Oesophageal Carcinoma |
2.2% |
| Head And Neck Cancer |
1.8% |
| Squamous Cell Carcinoma |
1.6% |
| Constipation |
1.6% |
| Neoplasm Malignant |
1.6% |
| Prostate Cancer Metastatic |
1.5% |
| Chemotherapy |
1.5% |
| Ovarian Cancer |
1.4% |
| Lung Neoplasm Malignant |
1.4% |
|
| Interstitial Lung Disease |
17.7% |
| Vomiting |
11.8% |
| White Blood Cell Count Decreased |
11.0% |
| Pyrexia |
7.7% |
| Death |
5.8% |
| Neutropenia |
4.6% |
| Respiratory Failure |
4.5% |
| Febrile Neutropenia |
3.4% |
| Sepsis |
3.4% |
| Pneumonia |
3.1% |
| Dyspnoea |
2.9% |
| Infusion Related Reaction |
2.8% |
| Shock |
2.8% |
| Renal Failure |
2.7% |
| Renal Failure Acute |
2.7% |
| Septic Shock |
2.7% |
| Stomatitis |
2.7% |
| Pneumonitis |
2.6% |
| Pulmonary Embolism |
2.6% |
| Weight Decreased |
2.4% |
|
| Secondary |
| Breast Cancer |
30.9% |
| Product Used For Unknown Indication |
10.7% |
| Prostate Cancer |
9.3% |
| Drug Use For Unknown Indication |
8.3% |
| Premedication |
7.0% |
| Breast Cancer Metastatic |
5.9% |
| Non-small Cell Lung Cancer |
4.0% |
| Breast Cancer Stage Ii |
3.7% |
| Prophylaxis |
2.7% |
| Chemotherapy |
2.2% |
| Hypertension |
2.1% |
| Head And Neck Cancer |
1.9% |
| Pain |
1.8% |
| Gastric Cancer |
1.7% |
| Oesophageal Carcinoma |
1.6% |
| Metastases To Bone |
1.5% |
| Prostate Cancer Metastatic |
1.2% |
| Nausea |
1.2% |
| Squamous Cell Carcinoma |
1.2% |
| Lung Neoplasm Malignant |
1.1% |
|
| Vomiting |
11.4% |
| Interstitial Lung Disease |
9.5% |
| Pyrexia |
8.3% |
| White Blood Cell Count Decreased |
8.0% |
| Febrile Neutropenia |
6.3% |
| Pneumonia |
5.7% |
| Neutropenia |
4.7% |
| Respiratory Failure |
4.5% |
| Death |
4.4% |
| Sepsis |
4.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
4.3% |
| Stomatitis |
3.7% |
| Dyspnoea |
3.7% |
| Pulmonary Embolism |
3.4% |
| Urinary Tract Infection |
3.4% |
| Alopecia |
3.2% |
| Rash |
3.0% |
| Disease Progression |
2.9% |
| Nausea |
2.8% |
| Tachycardia |
2.7% |
|
| Concomitant |
| Breast Cancer |
25.5% |
| Metastases To Bone |
14.4% |
| Breast Cancer Metastatic |
9.6% |
| Prostate Cancer |
6.9% |
| Drug Use For Unknown Indication |
5.9% |
| Chemotherapy |
5.2% |
| Pain |
5.0% |
| Product Used For Unknown Indication |
4.0% |
| Non-small Cell Lung Cancer |
3.3% |
| Prophylaxis |
2.5% |
| Prostate Cancer Stage Iv |
2.4% |
| Depression |
2.3% |
| Prostate Cancer Metastatic |
2.3% |
| Osteoporosis |
2.0% |
| Neoplasm Malignant |
1.8% |
| Premedication |
1.8% |
| Hypertension |
1.6% |
| Ovarian Cancer |
1.3% |
| Nausea |
1.2% |
| Lung Neoplasm Malignant |
1.1% |
|
| Tooth Extraction |
14.4% |
| Weight Decreased |
13.0% |
| Vomiting |
8.7% |
| Osteonecrosis |
6.9% |
| Toothache |
6.0% |
| Disease Progression |
4.5% |
| Death |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Pyrexia |
4.3% |
| Osteonecrosis Of Jaw |
4.2% |
| Wheezing |
4.1% |
| White Blood Cell Count Increased |
4.1% |
| Rash |
3.6% |
| Weight Increased |
3.0% |
| Febrile Neutropenia |
2.9% |
| Pain In Jaw |
2.9% |
| Pain |
2.5% |
| Prostate Cancer |
2.1% |
| Wound Dehiscence |
2.1% |
| Nausea |
2.0% |
|
| Interacting |
| Hiv Infection |
23.7% |
| Breast Cancer |
20.6% |
| Hormone Therapy |
14.4% |
| Product Used For Unknown Indication |
8.2% |
| Prostate Cancer |
8.2% |
| Atrial Fibrillation |
4.1% |
| Metastases To Bone |
4.1% |
| Drug Use For Unknown Indication |
3.1% |
| Squamous Cell Carcinoma |
3.1% |
| Nausea |
2.1% |
| Bipolar Disorder |
1.0% |
| Hypercholesterolaemia |
1.0% |
| Hypertension |
1.0% |
| Ischaemic Heart Disease Prophylaxis |
1.0% |
| Lung Adenocarcinoma |
1.0% |
| Lung Neoplasm Malignant |
1.0% |
| Prophylaxis Of Nausea And Vomiting |
1.0% |
| Prostate Cancer Metastatic |
1.0% |
|
| Drug Interaction |
16.0% |
| Diarrhoea |
8.0% |
| Oropharyngeal Candidiasis |
8.0% |
| Weight Decreased |
8.0% |
| Conjunctivitis |
4.0% |
| Febrile Neutropenia |
4.0% |
| Glottis Carcinoma |
4.0% |
| Hepatic Failure |
4.0% |
| Infusion Site Extravasation |
4.0% |
| Mixed Liver Injury |
4.0% |
| Mucosal Inflammation |
4.0% |
| Onycholysis |
4.0% |
| Potentiating Drug Interaction |
4.0% |
| Red Blood Cell Count Decreased |
4.0% |
| Renal Failure Acute |
4.0% |
| Septic Shock |
4.0% |
| Skin Exfoliation |
4.0% |
| Skin Toxicity |
4.0% |
| Stomatitis |
4.0% |
|
